title: Chemotherapy for Advanced Non-Small-Cell Lung Cancer in Elderly Patients.
abstract: OBJECTIVE
  Do patients above 70 years of age with newly diagnosed advanced non-small-cell lung cancer benefit from platinum-based combination or should they receive non-platinum agents either as single-agent or in combination?
  
  
  CONCLUSIONS
  For fit elderly patients platinum-based combination is associated with better overall survival, progression-free survival, and objective response rate, however this improvement should be counter balanced against the higher risk of major adverse events (AE).
authors.affiliation: Medical Oncology, Hospital São Carlos, Fortaleza, Brazil.
authors.forename: Fábio Nasser
authors.initials: FN
authors.lastname: Santos
authors.affiliation: Medical Oncology, Beneficência Portuguesa de São Paulo, São Paulo, Brazil.
authors.forename: Marcelo Rocha Souza
authors.initials: MR
authors.lastname: Cruz
authors.affiliation: Brazilian Cochrane Centre, Centro de Saúde Baseado em Evidência e Avaliação Tecnológica em Saúde, São Paulo, Brazil.
authors.forename: Rachel
authors.initials: R
authors.lastname: Riera
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D004358:Drug Therapy / Q000379:methods; D064420:Drug-Related Side Effects and Adverse Reactions / Q000473:pathology*; D006801:Humans; D009367:Neoplasm Staging; D010984:Platinum / Q000009:adverse effects* / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic
chemical_list: D010984:Platinum